Renovia, a medical technology company run by Marc Beer is evolving daily. Mandated to help manage urinary incontinence and pelvic floor disorders, this company has proven to help the community through the restoration of health. It uses unique pharmaceutical diagnostic and treatment devices approved by the Food and Drug Administration. According to a report recently published, about 250 million women in the world are suffering from pelvic floor disorders which makes Renovia a leader and ultimate health problem solver.
In 2018, Renovia made a major milestone as Leva was approved by the Food and Drug Administration for clinical use. This is just a highlight of many innovative and highly efficient devices and told the company has employed. Well, this comes with costs. Renovia is happy to announce that it has received a financial boost for its series B project at US$32 million and US$10 million in venture debt. This will help in the development and testing of Renovia products which could lead to better discoveries. Besides, this shares in the company’s mission which is to better diagnose and treat women with pelvic disorders as well as those suffering from urinary incontinence.
Marc Beer has always believed in coming up with workable health solutions that can satisfy the dynamic clients’ needs. He is excited about the interplay between the proprietary sensor technologies and health value information and believes if people commit to it then great treatment alternatives will be realized. He yearns for a time pelvic floor disorders will be managed using products that strengthen the muscles and help the patient get back to their normal self.
About Marc Beer
Marc Beer is a co-founder of Renovia alongside Yolanda Lorie and Ramon Iglesia who is the Managing Director. Beer holds the position of the Chief Executive Officer and is also the company’s chairman to the board of directors. He has had a very colorful and admirable medical career where he has contributed to paradigm shifts, growth and innovation. As a result, he has been honored severally.
He is motivated to go an extra mile whenever he finds a gap in the treatment of diseases. He believes that there are better ways to do things and if technology can optimally be utilized then this would disrupt the medical profession positively. Thanks to his determination, he made Viacell, a biotechnology company trade publicly in 2000. In 2005, Marc Beer again made history by leading Perkinelmer under the trademark of PKI to trade in the New York Stock Exchange. Learn more: https://www.linkedin.com/in/marcbeer
Marc Beer has held prestigious positions of leadership. He is affiliated to the Abbott Laboratories, Good Start Genetics, Minerva Neurosciences, Biotechnology Innovation Organization and also is a member of the Mass Life Science Board in Massachusetts just to highlight his career path. He studied Science at Miami University and is very passionate about alternative treatment options precisely in matters of infertility.